131I-labeled 5,10,15,20-tetrakis(4-hydroxyphenyl)porphyrin and 5,10,15,20-tetrakis(4-aminophenyl)porphyrin for combined photodynamic and radionuclide therapy

• DOI: 10.1007/s10967-018-5735-2
• Publication Date: 2018-02-13T10:26:07Z
• Authors: Hu Song; Guanquan Wang; Jing Wang; Yunhan Wang; Hongyuan Wei; Jiaheng He; Shunzhong Luo
• Keywords: Radionuclide therapy

Porphyrin derivatives are usually used for photodynamic therapy (PDT) and labeled with raidonuclide for radiopharmaceuticals. In this work, 5,10,15,20-tetrakis (4-hydroxyphenyl) porphyrin (TPPOH) and 5,10,15,20-tetrakis (4-aminophenyl) porphyrin (TPPNH2) were labeled by 131I. 131I-TPPOH and 131I-TPPNH2 were cultured with SMMC-7721 and HL-7702 cells for affinity test. The results show high uptake ratios of SMMC-7721 than HL-7702. 131I-TPPOH and 131I-TPPNH2 were performed radionuclide therapy (RNT) and PDT via tumor in situ injection. At 14 days post injection, the volumes of tumors injected 131I-TPPOH and 131I-TPPNH2 diminished 64 ± 11 and 54 ± 10%, respectively. The therapeutic effect is better than either single PDT or single RNT. The combination therapy of PDT and RNT could be a more effectual method for cancer therapy.